BMRN Biomarin Pharmaceutical Earnings and EPS analysis

EPS in 2026 (TTM): $1.4

Last Report Period Date: Mar 31, 2026

As of June 2026, according to Biomarin Pharmaceutical's latest financial report, the company's current EPS (TTM) is $1.4. Biomarin Pharmaceutical's EPS for 2025 came in at $1.82, marking a decrease from $2.25 in 2024. Biomarin Pharmaceutical's earnings per share for the quarterly report ending on Mar 31, 2026 was $0.55.

The annual EPS in 2025 was $1.82, a decrease of 19.1% from $2.25 in 2024. The quarterly EPS for the period ending Mar 31, 2026, was $0.55, marking a 43.3% decrease from the same quarter last year. BMRN's TTM EPS stands at $1.4 as of March 2026. Biomarin Pharmaceutical's EPS for 2024 stood at $2.25, a 152.8% increase from 2023.

Biomarin Pharmaceutical has recorded a decrease in EPS of 43.3% over the last 12 months (YoY, quarterly). For the last three years, BMRN recorded an average annual EPS growth rate of 33.8%. Biomarin Pharmaceutical had an average annual EPS growth rate of -17.4% over the last 5 years.